Key facts
- It has raised $127.5M; the latest was Later Stage VC ($89.7M) in Dec 2024.
- Notable investors include Johnson & Johnson JJDC, Brabantse Ontwikkelings Maatschappij, Forbion, Novartis Venture Fund, BioGeneration Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Citryll
- ·The full record, as it builds
Funding rounds
No funding rounds for Citryll are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Citryll
Developer of pharmaceutical drugs designed to treat autoimmune and other human diseases. The company's drugs include the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes, enabling doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage due to sepsis.
- Sector
- Healthcare
- HQ
- Oss, Netherlands
- Founded
- 2015
- Employees
- 31
- Website
- citryll.com/
- Ownership
- Privately Held (backing)
Citryll doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Citryll shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Citryll in its N-PORT filings yet. We sweep new filings monthly.